U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07714551) titled 'Zanzalintinib in Unresectable and Progressive MPGGs' on July 15.
Brief Summary: This study is to examine the effects of oral daily zanzalintinib in participants with unresectable, progressive metastatic pheochromocytoma or paraganglioma.
Study Start Date: Jan. 09, 2027
Study Type: INTERVENTIONAL
Condition:
Pheochromocytoma
Paraganglioma
Intervention:
DRUG: Zanzalintinib
Route: Oral Schedule: Daily
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Dana-Farber Cancer Institute
Information provided by (Responsible Party): Kimberly Perez, MD, Dana-Farber Cancer Institute
Published by HT Digital Content Services with permission ...